Prukaloprid (Serbo-Croatian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Prukaloprid" in Serbo-Croatian language version.

refsWebsite

Global rank Serbo-Croatian rank

10doi.org

2^nd place

7nih.gov

4^th place

3^rd place

2archive.org

6^th place

5^th place

2web.archive.org

1^st place

1sciencedirect.com

149^th place

32^nd place

1wikipedia.org

low place

1clinicaltrials.gov

5,225^th place

3,406^th place

1europa.eu

68^th place

64^th place

1hc-sc.gc.ca

low place

4,131^st place

archive.org

Bouras, E. P.; Camilleri, M.; Burton, D. D.; McKinzie, S. (1999). „Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans”. Gut 44 (5): 682–686. DOI:10.1136/gut.44.5.682. PMC 1727485. PMID 10205205.
Bouras, E. P.; Camilleri, M.; Burton, D. D.; Thomforde, G.; McKinzie, S.; Zinsmeister, A. R. (2001). „Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder”. Gastroenterology 120 (2): 354–360. DOI:10.1053/gast.2001.21166. PMID 11159875.

clinicaltrials.gov

Clinical Trials NCT00793247

doi.org

dx.doi.org

Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
Briejer, M. R.; Bosmans, J. P.; Van Daele, P.; Jurzak, M.; Heylen, L.; Leysen, J. E.; Prins, N. H.; Schuurkes, J. A. (2001). „The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound”. European Journal of Pharmacology 423 (1): 71–83. DOI:10.1016/S0014-2999(01)01087-1. PMID 11438309.
Emmanuel, A. V.; Kamm, M. A.; Roy, A. J.; Kerstens, R.; Vandeplassche, L. (2012). „Randomised clinical trial: The efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n = 1 study”. Alimentary Pharmacology & Therapeutics 35 (1): 48–55. DOI:10.1111/j.1365-2036.2011.04907.x. PMID 22061077.
Smart, C. J.; Ramesh, A. N. (2011). „The successful treatment of acute refractory pseudo-obstruction with Prucalopride”. Colorectal Disease: no. DOI:10.1111/j.1463-1318.2011.02929.x.
Bouras, E. P.; Camilleri, M.; Burton, D. D.; McKinzie, S. (1999). „Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans”. Gut 44 (5): 682–686. DOI:10.1136/gut.44.5.682. PMC 1727485. PMID 10205205.
Bouras, E. P.; Camilleri, M.; Burton, D. D.; Thomforde, G.; McKinzie, S.; Zinsmeister, A. R. (2001). „Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder”. Gastroenterology 120 (2): 354–360. DOI:10.1053/gast.2001.21166. PMID 11159875.
Tack, J.; Van Outryve, M.; Beyens, G.; Kerstens, R.; Vandeplassche, L. (2008). „Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives”. Gut 58 (3): 357–365. DOI:10.1136/gut.2008.162404. PMID 18987031.
Briejer, M. R.; Prins, N. H.; Schuurkes, J. A. (2001). „Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs”. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 13 (5): 465–472. DOI:10.1046/j.1365-2982.2001.00280.x. PMID 11696108.
Oustamanolakis, P.; Tack, J. (2012). „Prucalopride for chronic intestinal pseudo-obstruction”. Alimentary Pharmacology & Therapeutics 35 (3): 398. DOI:10.1111/j.1365-2036.2011.04947.x.

europa.eu

ema.europa.eu

„European Medicines Agency -EPAR”. Arhivirano iz originala na datum 2010-01-31. Pristupljeno 2014-04-05.

hc-sc.gc.ca

„Health Canada, Notice of Decision for Resotran”. Arhivirano iz originala na datum 2016-05-23. Pristupljeno 2014-04-05.

nih.gov

ncbi.nlm.nih.gov

Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
Briejer, M. R.; Bosmans, J. P.; Van Daele, P.; Jurzak, M.; Heylen, L.; Leysen, J. E.; Prins, N. H.; Schuurkes, J. A. (2001). „The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound”. European Journal of Pharmacology 423 (1): 71–83. DOI:10.1016/S0014-2999(01)01087-1. PMID 11438309.
Emmanuel, A. V.; Kamm, M. A.; Roy, A. J.; Kerstens, R.; Vandeplassche, L. (2012). „Randomised clinical trial: The efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction - a double-blind, placebo-controlled, cross-over, multiple n = 1 study”. Alimentary Pharmacology & Therapeutics 35 (1): 48–55. DOI:10.1111/j.1365-2036.2011.04907.x. PMID 22061077.
Bouras, E. P.; Camilleri, M.; Burton, D. D.; McKinzie, S. (1999). „Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans”. Gut 44 (5): 682–686. DOI:10.1136/gut.44.5.682. PMC 1727485. PMID 10205205.
Bouras, E. P.; Camilleri, M.; Burton, D. D.; Thomforde, G.; McKinzie, S.; Zinsmeister, A. R. (2001). „Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder”. Gastroenterology 120 (2): 354–360. DOI:10.1053/gast.2001.21166. PMID 11159875.
Tack, J.; Van Outryve, M.; Beyens, G.; Kerstens, R.; Vandeplassche, L. (2008). „Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives”. Gut 58 (3): 357–365. DOI:10.1136/gut.2008.162404. PMID 18987031.
Briejer, M. R.; Prins, N. H.; Schuurkes, J. A. (2001). „Effects of the enterokinetic prucalopride (R093877) on colonic motility in fasted dogs”. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 13 (5): 465–472. DOI:10.1046/j.1365-2982.2001.00280.x. PMID 11696108.

sciencedirect.com

Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

web.archive.org

„European Medicines Agency -EPAR”. Arhivirano iz originala na datum 2010-01-31. Pristupljeno 2014-04-05.
„Health Canada, Notice of Decision for Resotran”. Arhivirano iz originala na datum 2016-05-23. Pristupljeno 2014-04-05.

wikipedia.org

sh.wikipedia.org

Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit